Eva‐Laure Matera

1.3k total citations
32 papers, 815 citations indexed

About

Eva‐Laure Matera is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Eva‐Laure Matera has authored 32 papers receiving a total of 815 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Eva‐Laure Matera's work include Drug Transport and Resistance Mechanisms (6 papers), HER2/EGFR in Cancer Research (5 papers) and Microtubule and mitosis dynamics (4 papers). Eva‐Laure Matera is often cited by papers focused on Drug Transport and Resistance Mechanisms (6 papers), HER2/EGFR in Cancer Research (5 papers) and Microtubule and mitosis dynamics (4 papers). Eva‐Laure Matera collaborates with scholars based in France, United States and Switzerland. Eva‐Laure Matera's co-authors include Charles Dumontet, Kamel Chettab, Ahcène Boumendjel, Annabelle Gèze, Julien Boccard, Pierre‐Alain Carrupt, Minh Ngoc Duong, Madeleine Blanc, Denis Wouessidjewe and E. Nicolle and has published in prestigious journals such as Clinical Cancer Research, Journal of Medicinal Chemistry and Frontiers in Immunology.

In The Last Decade

Eva‐Laure Matera

32 papers receiving 802 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva‐Laure Matera France 16 355 314 145 88 82 32 815
Michelle L. Kraus United States 7 466 1.3× 447 1.4× 96 0.7× 101 1.1× 63 0.8× 9 1.1k
Andrew McGown United Kingdom 11 325 0.9× 228 0.7× 107 0.7× 56 0.6× 50 0.6× 28 661
Manuela Gridling Austria 13 672 1.9× 269 0.9× 126 0.9× 108 1.2× 35 0.4× 17 1.0k
Li-Yuan Bai Taiwan 17 466 1.3× 150 0.5× 82 0.6× 102 1.2× 35 0.4× 42 869
Robert A. Galemmo United States 19 494 1.4× 158 0.5× 262 1.8× 61 0.7× 40 0.5× 46 1.0k
Séverine Mollard France 11 444 1.3× 225 0.7× 61 0.4× 37 0.4× 49 0.6× 14 821
Matthew Labenski United States 12 405 1.1× 166 0.5× 200 1.4× 70 0.8× 68 0.8× 20 701
Christopher J. Matheson United States 13 647 1.8× 442 1.4× 130 0.9× 98 1.1× 21 0.3× 22 977
Linda Rickardson Sweden 18 705 2.0× 290 0.9× 82 0.6× 91 1.0× 31 0.4× 28 1.1k
Janet S. Macpherson United Kingdom 16 385 1.1× 333 1.1× 119 0.8× 69 0.8× 65 0.8× 30 861

Countries citing papers authored by Eva‐Laure Matera

Since Specialization
Citations

This map shows the geographic impact of Eva‐Laure Matera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva‐Laure Matera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva‐Laure Matera more than expected).

Fields of papers citing papers by Eva‐Laure Matera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva‐Laure Matera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva‐Laure Matera. The network helps show where Eva‐Laure Matera may publish in the future.

Co-authorship network of co-authors of Eva‐Laure Matera

This figure shows the co-authorship network connecting the top 25 collaborators of Eva‐Laure Matera. A scholar is included among the top collaborators of Eva‐Laure Matera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva‐Laure Matera. Eva‐Laure Matera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rébillard, Amélie, Amandine Thomas, Eva‐Laure Matera, et al.. (2024). Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice. Frontiers in Immunology. 15. 1368550–1368550. 6 indexed citations
2.
Chettab, Kamel, Chantel Fitzsimmons, А. В. Новиков, et al.. (2023). A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models. Frontiers in Immunology. 14. 1066402–1066402. 6 indexed citations
3.
Matera, Eva‐Laure, et al.. (2023). Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. Frontiers in Immunology. 13. 1011943–1011943. 6 indexed citations
4.
Wierinckx, Anne, Kamel Chettab, Fabian Birzele, et al.. (2022). In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies. Cancer Immunology Research. 10(8). 1013–1027. 18 indexed citations
5.
Chettab, Kamel, Eva‐Laure Matera, Maxime Lafond, et al.. (2022). Proof of Concept: Protein Delivery into Human Erythrocytes Using Stable Cavitation. Molecular Pharmaceutics. 19(3). 929–935. 5 indexed citations
6.
Duong, Minh Ngoc, Luis Molina, Kamel Chettab, et al.. (2020). Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib. BMC Pharmacology and Toxicology. 21(1). 61–61. 13 indexed citations
7.
Chettab, Kamel, et al.. (2020). Characterization of T‐DM1‐resistant breast cancer cells. Pharmacology Research & Perspectives. 8(4). e00617–e00617. 16 indexed citations
8.
Dumontet, Charles, Fabrice Gardebien, Romain Haudecoeur, et al.. (2018). Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models. European Journal of Medicinal Chemistry. 158. 405–413. 4 indexed citations
9.
Jordheim, Lars Petter, Kamel Chettab, Emeline Cros‐Perrial, Eva‐Laure Matera, & Charles Dumontet. (2018). Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. Pharmacology. 102(3-4). 161–168. 8 indexed citations
10.
Cornet, Sébastien, et al.. (2016). Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. Molecular Cancer Therapeutics. 15(6). 1238–1247. 11 indexed citations
11.
Grenot, Catherine, et al.. (2016). Deoxycholic acid derivatives as inhibitors of P-glycoprotein-mediated multidrug efflux. Steroids. 116. 5–12. 8 indexed citations
12.
Duong, Minh Ngoc, Eva‐Laure Matera, Kamel Chettab, et al.. (2015). Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Research. 17(1). 57–57. 91 indexed citations
13.
Jordheim, Lars Petter, Eva‐Laure Matera, Anne‐Laure Huber, et al.. (2013). Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors. Clinical Cancer Research. 19(13). 3556–3566. 13 indexed citations
14.
Jordheim, Lars Petter, Khaled Barakat, Eva‐Laure Matera, et al.. (2013). Small Molecule Inhibitors of ERCC1-XPF Protein-Protein Interaction Synergize Alkylating Agents in Cancer Cells. Molecular Pharmacology. 84(1). 12–24. 72 indexed citations
15.
Zeinyeh, Waël, Zahia Mahiout, Thierry Lomberget, et al.. (2012). Progesterone–adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological evaluation. Steroids. 77(12). 1177–1191. 8 indexed citations
16.
Hage‐Sleiman, Rouba, et al.. (2011). Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells. Molecular Cancer Therapeutics. 10(2). 303–312. 8 indexed citations
17.
Arnaud, Ophélie, Ahcène Boumendjel, Annabelle Gèze, et al.. (2011). The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. European Journal of Cancer. 47(4). 640–648. 31 indexed citations
18.
Hage‐Sleiman, Rouba, et al.. (2010). Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells. BMC Cancer. 10(1). 135–135. 20 indexed citations
19.
Matera, Eva‐Laure, et al.. (2009). β3‐Tubulin is induced by estradiol in human breast carcinoma cells through an estrogen‐receptor dependent pathway. Cell Motility and the Cytoskeleton. 66(7). 378–388. 23 indexed citations
20.
Béghin, Anne, et al.. (2006). ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. Experimental Cell Research. 313(3). 473–485. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle L. Kraus Breakdown of academic impact, for papers by Andrew McGown Breakdown of academic impact, for papers by Manuela Gridling Breakdown of academic impact, for papers by Li-Yuan Bai Breakdown of academic impact, for papers by Robert A. Galemmo Breakdown of academic impact, for papers by Séverine Mollard Breakdown of academic impact, for papers by Matthew Labenski Breakdown of academic impact, for papers by Christopher J. Matheson Breakdown of academic impact, for papers by Linda Rickardson Breakdown of academic impact, for papers by Janet S. Macpherson
Rankless by CCL
2026